慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究*

doi:10.3969/j.issn.1672-5069.2022.02.010

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)患者肝X受体α(LXRα)和细胞色素P450亚型7A1(CYP7A1)基因表达水平与肝组织病理学炎症和纤维化程度的关系。方法 2019年1月～2020年10月我院收治的CHB患者118例,均接受肝穿刺活检,将炎症活动度分级＞G2和肝纤维化分期＞S2定义为肝组织炎症或纤维化程度显著;采用免疫组织化学染色法检测肝组织LXRα和CYP7A1表达,采用RT-PCR法检测LXRα mRNA和CYP7A1 mRNA水平。结果 118例CHB患者肝组织LXRα和CYP7A1蛋白和/或其mRNA阳性分别为78.0%和73.7%;38例肝组织显著炎症组LXRα mRNA和其蛋白(AOD)水平分别为(0.6±0.2)和(0.3±0.1),显著高于80例非显著炎症患者[分别为(0.4±0.1)和(0.1±0.0),P<0.05],CYP7A1 mRNA和其蛋白(AOD)水平分别为(0.8±0.2)和(0.4±0.1),显著高于非显著炎症患者[分别为(0.3±0.1)和(0.1±0.0),P<0.05];48例显著肝纤维化组肝组织LXRα mRNA和其蛋白(AOD)水平分别为(0.7±0.2)和(0.3±0.1),显著高于70例非显著肝纤维化患者[分别为(0.3±0.1)和(0.1±0.1),P<0.05],CYP7A1 mRNA和其蛋白(AOD)水平分别为(0.7±0.2)和(0.3±0.1),显著高于非显著肝纤维化患者[分别为(0.4±0.2)和(0.2±0.1),P<0.05]。结论 LXRα和CYP7A1表达上调可能参与了CHB患者肝组织炎症和肝纤维化发生发展过程,其机制值得进一步研究。

关键词: 慢性乙型肝炎, 肝X受体α, 细胞色素P450亚型7A1, 肝组织学

Abstract: Objective The aim of this study was to explore the relationship between liver X receptor α (LXRα) and cytochrome P450 isoform 7A1 (CYP7A1) expression and liver histopathological inflammatory grading and fibrotic staging in patients with chronic hepatitis B (CHB). Methods 118 patients with CHB were enrolled in our hospital between January 2019 and October 2020, all patients underwent liver biopsies and histological activity >=G2 and liver fibrosis >=S2 were defined as significant inflammation or significant fibrosis. The expression and their mRNA levels of LXRα and CYP7A1 in liver tissues were detected by immunohistochemical staining and by RT-PCR. Results The positive rates of hepatic LXRα和CYP7A1mRNA and/or their proteins in 118 patients with CHB were 78.0% and 73.7%, respectively; the LXRα mRNA level and its protein expression in 38 patients with significant liver inflammation were (0.6±0.2) and (0.3±0.1)average optical density (AOD), significantly higher or stronger than [(0.4±0.1) and (0.1±0.0)AOD, respectively, P<0.05] in 80 patients without significant hepatic histopathological inflammation, and the CYP7A1 mRNA level and its protein expression were (0.8±0.2) and (0.4±0.1)AOD, significantly higher or stronger than [(0.3±0.1) and (0.1±0.0)AOD, respectively, P<0.05] in patients without significant hepatic inflammation; the LXRα mRNA and its protein expression in 48 patients with significant liver fibrosis were (0.7±0.2) and (0.3±0.1)AOD, significantly higher or stronger than [(0.3±0.1) and (0.1±0.1)AOD, P<0.05] in 70 patients without significant liver fibrosis, and the CYP7A1 mRNA level and its protein expression were (0.7±0.2)and (0.3±0.1)AOD, significantly higher or stronger than [(0.4±0.2) and (0.2±0.1)AOD, respectively, P<0.05] in patients without significant liver fibrosis. Conclusion The up-regulation of LXRα and CYP7A1 gene might be involved in the pathogenesis of liver inflammation and fibrosis, which needs further investigation.

Key words: Hepatitis B, Liver X receptor α, Cytochrome P450 isoform 7A1, Liver histology

李振, 宁姗姗, 郭影, 王甜甜, 李莉华, 叶美红, 宋源源. 慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 191-194.

Li Zhen, Ning Shanshan, Guo Ying, et al. Hepatic expression of liver X receptorα and cytochrome P450 isoform 7A1 in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(2): 191-194.

参考文献

[1] Mesnage R, Renney G, Séralini GE, et al. Author correction: multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of roundup herbicide. Sci Rep,2018,8(1):12572-12578.
[2] Wong YJ, Kalki RC, Lin KW, et al. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. Singapore Med J,2020,61(8):419-425.
[3] 邓羊羊,葛善飞,余燕青,等. 肝细胞核因子1α在慢性乙型肝炎患者肝脏炎症及纤维化发生发展过程中的表达变化及其意义. 中华肝脏病杂志,2021,29(2):121-125.
[4] Chen PC, Chen BH, Huang CH, et al. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol,2019,31(10):1256-1263.
[5] Suliman I, Abdelgelil N, Kassamail F, et al. The effect of hepatic steatotis on the natural history of HBV infection. Clin Liver Dis,2019,23(3):443-450.
[6] Zeng J, Wu D, Hu H, et al. Activation of the liver x receptor pathway inhibits HBV replication in primary human hepatocytes. Hepatology,2020,72(6):1935-1948.
[7] Mak JSM, Lao TT, Leung MBW, et al. Ovarian HBV replication following ovulation induction in female hepatitis B carriers undergoing ivf treatment: a prospective observational study. J Viral Hepat,2020,27(2):110-117.
[8] 吴文楠,曾勇彬,林锦骠,等. 福建省汉族乙型肝炎病毒感染者胆固醇7α-羟化酶基因的多态性分析. 中华检验医学杂志,2018,41(2):155-164.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[10] 周志凌,印倩. 慢性乙型肝炎病毒携带者血清GP73水平与肝组织病理学变化的关系研究. 实用肝脏病杂志,2018,21(5):717-720.
[11] Grinman DY, Careaga VP, Wellberg EA, et al. Liver x receptor-α activation enhances cholesterol secretion in lactating mammary epithelium. Am J Physiol Endocrinol Metab,2019,316(6):1136-1145.
[12] Wu HM, Kim TH, Kim A, et al. Liverx receptor α-induced cannabinoid receptor 2 inhibits ubiquitin-specific peptidase 4 through mir-27b, protecting hepatocytes from TGF-β. Hepatol Commun,2019,3(10):1373-1387.
[13] Eid SA, El Massry M, Hichor M, et al. Targeting the nadph oxidase-4 and liver x receptor pathway preserves schwann cell integrity in diabetic mice. Diabetes,2020,69(3):448-464.
[14] Zinkhan EK, Yu B, McKnight R. Uteroplacental insufficiency impairs cholesterol elimination in adult female growth-restricted rat offspring fed a high-fat diet. Reprod Sci,2019,26(9):1173-1180.
[15] Zuo H, Su X, Jin Y, et al. Transthyretin regulated by linc00657/mir-205-5p promoted cholesterol metabolism by inducing srebp2-hmgcr and inhibiting lxrα-cyp7a1. Arch Med Res,2020,51(4):317-326.
[16] Zhou Y, Chen Z, Lin Q, et al. Nuciferine reduced fat deposition by controlling triglyceride and cholesterol concentration in broiler chickens. Poult Sci,2020,99(12):7101-7108.
[17] Srivastava RAK, Cefalu AB, Srivastava NS, et al. Npc1l1 and abcg5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with ppar-α and lxr agonists. Mol Cell Biochem,2020,473(1):247-262.
[18] 王俐钧,孙建光. 基于LXRα/FAS通路探讨茵杞调脂饮治疗大鼠非酒精性脂肪肝病的作用机制. 中华中医药杂志,2019,34(10):4566-4570.
[19] Song XY, Wu WF, Gabbi C, et al. Retinal and optic nerve degeneration in liver x receptorβ knockout mice. Proc Natl Acad Sci USA,2019,116(33):16507-16512.

慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*

Hepatic expression of liver X receptorα and cytochrome P450 isoform 7A1 in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[2]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[3]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[4]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[5]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[6]	周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.
[7]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[8]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[9]	吴慧, 宋波, 吕承秀, 田文君, 牛家峰. 慢性乙型肝炎患者血清内质网应激指标变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(4): 484-487.
[10]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[11]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[12]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[13]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[14]	张思薇, 孔银, 刘天府, 刘元元, 麻爱娣, 李永芳, 李娟, 张岭漪. 肝脏硬度检测联合吲哚菁绿滞留率测定对血清转氨酶正常或轻度升高的慢性乙型肝炎患者肝组织学病变进展的预测价值[J]. 实用肝脏病杂志, 2021, 24(2): 184-187.
[15]	杨永启, 郭彦东, 李鸿彬. 慢性乙型肝炎患者肠粘膜病变观察[J]. 实用肝脏病杂志, 2021, 24(2): 188-191.